Patents Assigned to New York Blood Center
  • Patent number: 10137107
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 27, 2018
    Assignees: New York Blood Center, Inc., National Institutes of Health
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 9982230
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 29, 2018
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 9943589
    Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: April 17, 2018
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Shibo Jiang, Lanying Du
  • Patent number: 9889194
    Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 13, 2018
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou, Guangyu Zhao
  • Patent number: 9803164
    Abstract: Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 31, 2017
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventor: Beau W. Mitchell
  • Patent number: 9724383
    Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: August 8, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
  • Patent number: 9701736
    Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: July 11, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou
  • Patent number: 9592287
    Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 14, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du
  • Patent number: 9574178
    Abstract: Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: February 21, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: W. Beau Mitchell, Mauro P. Avanzi
  • Patent number: 9480786
    Abstract: Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: November 1, 2016
    Assignee: The New York Blood Center, Inc.
    Inventors: Christopher D. Hillyer, Beth H. Shaz
  • Patent number: 9394518
    Abstract: This disclosure provides methods for preparing both a red blood cell (RBC)-containing product and a platelet-containing product from a plurality of blood units. The method comprises leukoreducing a plurality of blood units, separating RBCs, platelets, and plasma from the units to form leukoreduced blood components, pooling the leukoreduced RBC components; pooling the leukoreduced platelet components, treating the pooled components to inactivate one or more pathogens, adding a storage solution to components, dividing the pooled leukoreduced RBCs into a plurality of RBC-containing product units, each having a uniform number of RBCs, and dividing the pooled leukoreduced platelets into a plurality of platelet-containing product units, each having a uniform number of platelets.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 19, 2016
    Assignee: The New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 9309237
    Abstract: Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: April 12, 2016
    Assignees: NEW YORK BLOOD CENTER, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 9255140
    Abstract: The present disclosure relates to a method for inducing an antigen-specific immune response to an antigen in a mammal in need thereof, or potentiating an immune response, by administering to the mammal an effective amount of an isolated Ov-ASP, or at least one subunit of Ov-ASP.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: February 9, 2016
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 9115186
    Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: August 25, 2015
    Assignee: New York Blood Center
    Inventors: Shibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
  • Patent number: 9052325
    Abstract: Systems and methods are provided for assessing the risk of hemolytic disease of the fetus or neonate, neonatal alloimmune thrombocytopenic purpura, or transfusion-associated lung injury in a patient or transfusion recipient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventor: Gregory R. Halverson
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 8968993
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: March 3, 2015
    Assignee: The New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 8940864
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 27, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 8937154
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: January 20, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 8933019
    Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: January 13, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli